Innate Pharma SA (IPHA) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive...

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome...

Innate Pharma annonce le traitement du premier patient dans l’essai de Phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées

IPH4502 est un nouveau conjugué anticorps-médicament ciblant Nectine-4 et différencié à base d’exatecan, un inhibiteur de topoisomérase I, comme...

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Regulatory News: Innate Pharma SA...

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma annonce une stratégie de transformation pour accélérer sa croissance

 Une stratégie axée sur le développement clinique précoce de molécules propriétaires présentant un potentiel en monothérapie : Stimuler...

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its management will...